Citigroup Forecasts Strong Price Appreciation for Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics (NASDAQ:APGE) had its price objective lifted by Citigroup from $95.00 to $125.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price target suggests a potential upside of 69.74% from the company’s previous close.

Other research analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Apogee Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Wolfe Research initiated coverage on shares of Apogee Therapeutics in a research report on Wednesday, January 7th. They issued a “peer perform” rating for the company. UBS Group raised shares of Apogee Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 7th. Craig Hallum reiterated a “buy” rating and set a $116.00 price target on shares of Apogee Therapeutics in a research report on Wednesday, January 7th. Finally, BTIG Research restated a “buy” rating and issued a $137.00 price objective on shares of Apogee Therapeutics in a report on Monday. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.43.

Apogee Therapeutics Trading Down 7.1%

Shares of APGE stock traded down $5.60 during trading hours on Tuesday, reaching $73.64. The company’s stock had a trading volume of 502,887 shares, compared to its average volume of 1,017,393. The stock has a market capitalization of $5.12 billion, a P/E ratio of -17.40 and a beta of 1.39. Apogee Therapeutics has a one year low of $26.20 and a one year high of $84.56. The firm’s fifty day simple moving average is $71.28 and its 200 day simple moving average is $63.70.

Apogee Therapeutics (NASDAQ:APGE) last posted its earnings results on Monday, March 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.02. As a group, equities research analysts forecast that Apogee Therapeutics will post -3.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Carl Dambkowski sold 5,500 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $71.06, for a total transaction of $390,830.00. Following the completion of the transaction, the insider owned 209,773 shares of the company’s stock, valued at $14,906,469.38. This trade represents a 2.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Fairmount Funds Management Llc sold 1,750,000 shares of Apogee Therapeutics stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $76.30, for a total value of $133,525,000.00. Following the transaction, the director owned 298,647 shares of the company’s stock, valued at $22,786,766.10. The trade was a 85.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,839,700 shares of company stock worth $140,118,083 in the last 90 days. Insiders own 42.77% of the company’s stock.

Hedge Funds Weigh In On Apogee Therapeutics

Several large investors have recently modified their holdings of the stock. Rockefeller Capital Management L.P. bought a new position in Apogee Therapeutics in the 4th quarter worth about $25,000. ANTIPODES PARTNERS Ltd increased its stake in Apogee Therapeutics by 41.2% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock valued at $33,000 after purchasing an additional 246 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in Apogee Therapeutics during the 4th quarter valued at about $37,000. Quantbot Technologies LP purchased a new position in Apogee Therapeutics in the third quarter worth about $96,000. Finally, Seven Fleet Capital Management LP purchased a new position in Apogee Therapeutics in the fourth quarter worth about $136,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Key Headlines Impacting Apogee Therapeutics

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive 52‑week Phase 2 APEX data for zumilokibart showed durable maintenance and deepening of responses (EASI‑75 maintenance ~75% Q3M and ~85% Q6M; strong vIGA results), supporting the drug’s clinical profile and commercial potential. GlobeNewswire release
• Positive Sentiment: Multiple sell‑side upgrades and large price‑target increases (Guggenheim to $160, Canaccord to $130, BTIG reaffirmed $137) signal renewed analyst conviction and imply significant upside versus pre‑news levels. Benzinga
• Neutral Sentiment: Investor commentary and analysis (Seeking Alpha slides/transcript and valuation notes) highlight durable efficacy, convenient infrequent dosing (Q3M/Q6M) and a solid cash position — these support the bull case but also note valuation/near‑term catalysts and M&A considerations. Seeking Alpha
• Neutral Sentiment: Company hosted/announced a conference call and slide deck to discuss the 52‑week data — useful for investors wanting detail on durability, safety and positioning versus competitors. Yahoo/Conference Call
• Negative Sentiment: Apogee announced a proposed $300M underwritten public offering (with a 30‑day upsize option), which introduces near‑term dilution risk and commonly puts downward pressure on the stock while the offering is live. This is the most likely proximate cause of the intraday pullback. GlobeNewswire offering notice
• Neutral Sentiment: Reported short‑interest data in the feed is inconsistent/insignificant (shows 0 shares), so it provides no clear signal on bearish positioning. Short interest note

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.